HOPO Therapeutics leverages our world-class expertise to address the most pressing unmet needs at the intersection of heavy metals and human health. For us, the term “heavy metals” includes environmental pollutants like lead, cadmium, arsenic, and mercury, as well as the lanthanide elements, many of which are considered critical materials for energy and technology applications. We also include the radioactive actinide elements that drive our nuclear power plants, medical technologies, space vehicles, and nuclear weapons.

We are developing pharmaceuticals designed to treat exposure to heavy metals, beginning with our flagship drug candidate HOPO 14-1. A clinical-stage oral formulation of our platform molecule HOPO-101, it has manifold applications in heavy metal poisoning.